Our score was derived and internally validated using a cohort of 1,264 adult patients who presented with a new VTE to a large tertiary hospital in Buenos Aires. Our study had a shorter follow-up period of 12 months, but patients in our cohort had a similar risk (9.2%) of having an associated occult cancer identified during follow-up. Similar to the findings from Jara-Palomares and colleagues, our final predictive score included previous episode of VTE, underlying comorbidities (as measured by the Charlson comorbidity score), and recent surgery. However, our methodology also included a secondary analysis evaluating a combined outcome of cancer or death to address the possibility that death might occur before the identification of an occult cancer. In this model, additional predictive factors were age ≥ 70 years and an albumin level ≤ 2.5 mg/dL. We believe this is an important issue not addressed in the study by Jara-Palomares and colleagues, because death was frequent during our 1 year of follow-up, occurring in 72% of patients with occult cancer and 19% without cancer.